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The proteasome is emerging as a target for cancer
therapy because small molecule inhibitors of its cata-
lytic activity induce apoptosis in both in vitro and in
vivo models of human malignancies and are proving to
have efficacy in early clinical trials. To further elucidate
the mechanism of action of these inhibitors, their im-
pact on signaling through the p44/42 mitogen-activated
protein kinase (MAPK) pathway was studied. Protea-
some inhibition with either carbobenzoxy-leucyl-leucyl-
phenylalaninal or lactacystin led to a loss of dually phos-
phorylated, activated p44/42 MAPK in A1N4-myc human
mammary and MDA-MB-231 breast carcinoma cells in a
dose- and time-dependent fashion. This correlated with
an induction of the dual specificity MAPK phosphatases
(MKP)-1 and -2, and blockade of MKP induction using
either actinomycin D or Ro-31-8220 significantly de-
creased loss of activated p44/42 MAPK. Inhibition of
p44/42 MAPK signaling by use of the MAPK kinase in-
hibitors PD 98059 or U0126, or by use of a dominant
negative MAPK construct, enhanced proteasome inhib-
itor-mediated apoptosis. Conversely, activation of
MAPK by epidermal growth factor, or use of a mutant
MAPK resistant to MKP-mediated dephosphorylation,
inhibited apoptosis. These studies support a role for
inactivation of signaling through the p44/42 MAPK path-
way in proteasome inhibitor-mediated apoptosis.
Eukaryotic intracellular protein degradation occurs predom-
inantly through the ubiquitin (Ub)1-proteasome pathway, com-
posed of the Ub-conjugating system and the 26 S proteasome
(reviewed in Refs. 1–5). The former labels proteins with ubiq-
uitin chains in preparation for recognition by the 26 S protea-
some, whereas the latter contains the 20 S multicatalytic pro-
teinase complex (1–5), with its proteolytically active subunits
(reviewed in Ref. 6). Ub-proteasome pathway activity is essen-
tial for such fundamental cell functions as the timely degrada-
tion of cyclins, cyclin-dependent kinases, and cyclin-dependent
kinase inhibitors (reviewed in Ref. 7), processing and degrada-
tion of transcription factors, short-lived regulatory proteins
(1–5), antigen processing (reviewed in Ref. 8), and angiogenesis
(9). A role for the proteasome in programmed cell death was
uncovered using small molecular weight, cell-permeable inhib-
itors, which induce apoptosis in a variety of tumor-derived cell
lines (reviewed in Refs. 10–12). In some cases the apoptotic
program is preferentially activated in transformed cells, with
relative sparing of nontransformed cells (13–15). Proteasome
inhibitors have induced apoptosis and tumor growth delay in
xenograft models of human malignancies (13, 16–18). Most
recently, proteasome inhibitors have entered clinical trials, and
preliminary evidence of significant anti-tumor activity has
been reported (19).
It has been hypothesized that proteasomes act at a pre-
mitochondrial, pre-caspase stage of apoptosis in some systems
(10–12, 20). Given the importance of the proteasome to normal
cellular homeostasis, however, it is likely that inhibitors induce
programmed cell death by affecting many apoptosis-associated
pathways. Indeed, evidence has been presented that, at least in
some systems, has implicated roles for p53 accumulation (see,
for example, Ref. 21), activation of c-Jun N-terminal kinase
(22), and accumulation of p27Kip1 (see, for example, Ref. 23).
Investigations have also supported the importance of blockade
of nuclear translocation of NF-B (see, for example, Refs. 24
and 25), inhibition of degradation of pro-apoptotic Bid (26), and
activation of the Fas-Fas ligand signaling system (27) in pro-
teasome inhibitor-mediated apoptosis (reviewed more fully in
Refs. 10–12).
Some of the more ubiquitous cellular signaling cascades are
the mitogen-activated protein kinase (MAPK) pathways, in-
cluding the p44/42 MAPK, also called the extracellular signal-
related kinases, or ERK-1/2. These pathways play important
roles in a variety of processes, including cell development,
differentiation, inflammation, and apoptosis (reviewed in Refs.
28–30). A possible role for the proteasome in ERK-1/2 signaling
has been suggested by studies with the peptidyl aldehyde in-
hibitor N-acetyl-Leu-Leu-norleucinal (ALLN), that targets
both calpains and the proteasome (31–33), and induces nuclear
accumulation of p44/42 MAPK in CCL39 Chinese hamster lung
fibroblasts (34). The cysteine proteinase inhibitors calpeptin
and E64D have been reported to inactivate MAPK function in
Balb/c 3T3 cells by inducing MAPK phosphatase (MKP)-1, but
ALLN did not exhibit a similar ability in these cells (35). In
contrast, other studies in CCL39 cells reported that ALLN does
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indeed induce MKP-1 (36), but its impact on p44/42 MAPK was
not investigated. Recent work with the proteasome inhibitor
PS-341 (16) suggested that phosphorylation of p44/42 MAPK
was decreased (37), but the impact of proteasome-specific in-
hibitors on the activation status of ERK-1/2 has not been well
characterized. Furthermore, a role for this pathway in the
induction of programmed cell death by proteasome inhibitors
has not been described, and we therefore sought to investigate
this possibility further.
In the current report, we present data demonstrating that
inhibition of the proteasome in breast epithelial and breast
carcinoma cells resulted in inhibition of signaling through
ERK-1/2 by a decrease in the abundance of the active, dually
phosphorylated kinases. This decrease was accompanied by the
induction of MKP-1 and -2, and both occurred in a time- and
concentration-dependent fashion. Blockade of MKP induction
significantly inhibited MAPK dephosphorylation, suggesting
that the two were closely linked. Inhibition of p44/42 MAPK
signaling using both pharmacologic and dominant negative
mutant constructs enhanced proteasome inhibitor-mediated
apoptosis, whereas activation of MAPK by pharmacologic or
genetic means decreased this programmed-cell death. These
studies support a role for inhibition of MAPK signaling in the
induction of programmed cell death by proteasome inhibitors.
EXPERIMENTAL PROCEDURES
Materials—The proteasome inhibitor carbobenzoxy-leucyl-leucyl-
phenylalaninal (Z-LLF-CHO), synthesized by oxidation of the corre-
sponding peptidyl alcohol, Z-LLF-OH, as previously described (38), was
purified by crystallization from ethanol/water, whereas lactacystin was
obtained from Calbiochem-Novabiochem Corp. (San Diego, CA). Phos-
phatase inhibitors deltamethrin, nodularin, and okadaic acid were from
Calbiochem-Novabiochem Corp., whereas sodium orthovanadate was
from Sigma. Actinomycin D and phenylmethylsulfonyl fluoride (PMSF)
were from Fisher Scientific (Fair Lawn, NJ), whereas Ro-31-8220 was
from Calbiochem-Novabiochem Corp., as was the MEK inhibitor PD
98059, and U0126 was from Promega Corp. (Madison, WI). Stock solu-
tions and serial dilutions were prepared in 100% ethanol (Z-LLF-OH,
Z-LLF-CHO, and PMSF; Mallinckrodt Baker, Inc., Paris, KY), 100%
methanol (actinomycin D; Fisher Scientific), phosphate-buffered saline
(sodium orthovanadate (PBS); 1 PBS, 9.1 mM dibasic sodium phos-
phate, 1.7 mM monobasic sodium phosphate, 150 mM NaCl, pH 7.4;
obtained from the Lineberger Comprehensive Cancer Center Tissue
Culture Facility (LCCC TCF)), or dimethyl sulfoxide (Fisher Scientific)
for all others, and stored at 20 °C. These reagents were used at
concentrations indicated in the text, with a final vehicle concentration
that did not exceed 0.5% (v/v). All other chemicals, unless otherwise
indicated, were obtained from Fisher Scientific.
Cell Lines and Cell Culture—A1N4-myc cells (39), the generous gift
of Dr. R. B. Dickson (Georgetown University, Washington, DC), were
grown in Richter’s modified Eagle’s medium with insulin, gentamicin,
and 20 mM Hepes (LCCC TCF), and further supplemented with human
recombinant epidermal growth factor (EGF) at 10 ng/ml unless other-
wise indicated, 9% fetal bovine serum, penicillin G sodium at 100
units/ml, streptomycin sulfate at 100 g/ml (these reagents from In-
vitrogen), and hydrocortisone (39) (Sigma). MDA-MB-231 (40) and BT-
474 (41) human breast carcinoma cells (LCCC TCF) were grown in
Richter’s modified Eagle’s medium as above except without EGF and
hydrocortisone. All cells were propagated in incubators providing a
humidified atmosphere with 5% CO2 in air.
Evaluation of p44/42 MAPK Activation Status—Adherent cells were
detached by exposure to trypsin (Invitrogen), counted using a hemacy-
tometer (Hausser Scientific, Horsham, PA), and 2  106 cells were
seeded onto 60-mm Falcon 3002 tissue culture plates (BD PharMingen
Labware, Lincoln Park, NJ) in complete medium. These cells were
allowed to reattach overnight and subjected to conditions described in
the text along with the addition of fresh medium. At the completion of
an experiment, all plates were placed on ice, washed with 5 ml of
ice-cold PBS, and collected by scraping into eukaryotic lysis buffer (10
mM Tris-hydrochloride (HCl), pH 7.4, 2% sodium dodecyl sulfate (SDS),
5 mM EDTA, 100 g/ml PMSF, 1 nM deltamethrin, 180 nM nodularin,
and 100 M sodium orthovanadate). Lysates were immediately dena-
tured by heating to 95–100 °C for 10 min, and after the removal of
aliquots for protein assays, samples were reduced by heating for an-
other 5 min at 95–100 °C in 1 SDS sample buffer (31.25 mM Tris-HCl,
pH 6.8, 2% SDS, 5% mercaptoethanol, 10% sucrose, and 0.005% brom-
phenol blue). Relative protein concentrations of each sample were de-
termined using the BCA protein assay kit (Pierce).
Equivalent protein amounts were subjected to SDS-polyacrylamide
gel electrophoresis (SDS-PAGE) with the Broad Range Biotinylated
Protein Marker set (New England Biolabs, Beverly, MA) and/or the Low
Range Prestained SDS-PAGE Standards (Bio-Rad) using the Mini-
PROTEAN II electrophoresis system (Bio-Rad). A discontinuous buffer
system essentially according to Laemmli was used (42), and separated
proteins were then electrophoretically transferred to BA85 Protran
nitrocellulose filters (Schleicher & Schuell) using a Mini-PROTEAN II
blotting system (Bio-Rad). These were blocked with a solution of nonfat
dry milk (Nestle USA, Inc., Solon, OH) in 20 mM Tris-HCl, pH 7.4, 140
mM NaCl, 0.10% Tween 20, and exposed to the indicated antibodies
diluted in this same solution. Horseradish peroxidase (HRP)-conju-
gated anti-rabbit (New England Biolabs or Bio-Rad), anti-mouse (Am-
ersham Biosciences), or anti-rat (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA) secondary antibodies were then used, with an anti-biotin
HRP-conjugated antibody (New England Biolabs) as needed. Immuno-
reactive protein bands were detected using either the Phototope-HRP
Western detection kit (New England Biolabs) or the ECL detection
system (Amersham Biosciences), Kodak Biomax ML film, and a Kodak
model M6B RP X-Omat film processor (Eastman Kodak Co.). For re-
peated analyses of the same filter, blots were stripped for 45 min using
Western Re-Probe (Geno Technology, Inc., St. Louis, MO) following the
manufacturer’s specifications.
Activation status of the p44/42 MAPKs was determined using murine
monoclonal antibodies recognizing active, dually phosphorylated p44/42
(Thr-202/Tyr-204), with rabbit p44/42 antibodies used as loading con-
trols. The activation status of the mitogen-activated protein kinase
kinase (MEK) was determined using rabbit polyclonal antibodies rec-
ognizing active, dually phosphorylated MEK-1/2 (Ser-217/Ser-221),
with rabbit MEK-1/2 antibodies (all from Cell Signaling Technology,
Inc., Beverly, MA) used as loading controls. Additional loading controls
were provided by rat monoclonal antibodies 1B5 to HSC-70 and 9G10 to
GRP-94 (StressGen Biotechnologies Corp., Victoria, British Columbia,
Canada), the former a generous gift of Dr. J. Spychala.
To quantify protein bands, autoradiographs were scanned with an
Agfa Duoscan T2500 scanner (Agfa Corp., Ridgefield Park, NJ) into
Adobe Photoshop 5.0 (Adobe Systems, Inc., San Jose, CA), and densi-
tometry was performed using NIH Image version 1.61. These proce-
dures were performed by members of the laboratory who were blinded
to the experimental conditions.
Evaluation of Phosphatase Expression—Western blotting performed
as described above was used to evaluate the expression of the MKP-1
and -2 phosphatases. Primary antibodies used included rabbit poly-
clonal C-19 antibody to MKP-1 and S-18 to MKP-2 (Santa Cruz Bio-
technology, Inc.). To inhibit phosphatases in intact cells, A1N4-myc and
MDA-MB-231 lines were pre-incubated for 60 min with either sodium
orthovanadate at 1 mM, okadaic acid at 30 nM, or both, and then
subjected to conditions as described in the text and processed and
analyzed as noted above. MKP-1 and -2 induction was inhibited by
pre-incubation of cells for 60 min with either actinomycin D at 3.0
g/ml, or Ro-31-8220 at 5.0 M.
Apoptosis Assays—For apoptosis experiments cells were seeded onto
either Falcon 3226 24-well plates (BD PharMingen Labware) at a
density of 1  105 cells/well or Costar 3595 96-well plates (Corning Inc.,
Corning, NY) at a density of 1  104 cells/well in complete medium,
unless indicated otherwise. Fresh medium was added containing the
agents for which impact was being tested, and cells were analyzed for
apoptosis using the Cell Death Detection ELISAPLUS kit (Roche Molec-
ular Biochemicals). Spectrophotometric data at a wavelength of 405
nm, with a reference of 490 nm, were acquired on a MAXline Vmax
kinetic microplate reader (Molecular Devices Corp., Sunnyvale, CA).
The enhancement of apoptosis induced by each condition was calculated
in relation to parallel control cells which received vehicle alone, and
tabulated in KaleidaGraph version 3.0.1 (Synergy Software, Reading,
PA). Mean percentages and standard errors of the mean were then
calculated and plotted in KaleidaGraph.
Cloning and Cell Line Preparation—The hyperactive, phosphatase-
resistant allele of ERK2 (D319N) (43), as well as a dominant negative
ERK2 allele (K52R) (44), both tagged with hemagglutinin, were gener-
ous gifts of Dr. C. Der (University of North Carolina, Chapel Hill, NC).
These were cloned into the vector pLPCX (CLONTECH), where expres-
sion is driven by the human cytomegalovirus immediate early pro-
moter, and verified by sequencing (DNA Sequencing Core Facility,
Lineberger Comprehensive Cancer Center, Chapel Hill, NC). Stable cell
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lines were prepared in BT-474 cells by transfection using the GenePOR-
TERTM reagent according to the manufacturer’s specifications (Gene
Therapy Systems, San Diego, CA), followed by selection in medium
containing puromycin (Calbiochem-Novabiochem Corp.). Colonies were
screened for mutant ERK expression by Western blotting, as described
above, using a murine anti-hemagglutinin monoclonal antibody (F7;
Santa Cruz Biotechnology, Inc.).
To prepare A1N4-myc- and MDA-MB-231-based cell lines, the indi-
cated ERK clones were transfected into AmphoPackTM-293 cells using
the CalPhosTM mammalian transfection kit (both from CLONTECH)
according to the manufacturer’s specifications. Supernatants with ret-
roviral particles were collected and used to infect the target cells in
medium containing 8 M Polybrene. Selection and screening of clones
was performed as described above.
RESULTS
Proteasome Inhibitors Decrease Signaling through p44/42
MAPK—To determine the impact of proteasome inhibition on
ERK-1/2 pathway signaling immortalized A1N4-myc cells, de-
rived from benzo(a)pyrene-treated normal human mammary
epithelium (39), and MDA-MB-231 human mammary carci-
noma cells (40) were studied. Analysis of extracts after mock
treatment or exposure to vehicle revealed significant levels of
dually phosphorylated, active p44 and p42 MAPK in A1N4-myc
(Fig. 1A, left panel) and MDA-MB-231 cells (Fig. 1A, right
panel). When these cells were exposed to Z-LLF-OH, a precur-
sor peptidyl alcohol with no activity as a proteasome inhibitor
(38, 45), phospho-MAPK levels were unchanged. Treatment
with the active peptidyl aldehyde proteasome inhibitor Z-LLF-
CHO, however, resulted in decreased levels of phospho-ERK-1
and -2, which were not because of a loss of p44/42 protein. Total
MAPK levels were themselves unchanged, as determined by
evaluation for an unrelated protein, the heat shock cognate
protein HSC-70. Many of the proteasome inhibitors previously
used in studies of the p44/42 MAPK pathway (34, 35) have been
peptides that also inhibit calpains, and Z-LLF-CHO falls into
this category as well (31–33). Because more specific calpain
inhibitors have also been reported to induce inhibition of
MAPK function (35), we evaluated the impact of the specific
proteasome inhibitor lactacystin (46). This agent also induced a
loss of dually phosphorylated p44 and p42 MAPK (Fig. 1A),
demonstrating that in these cells proteasome inhibition was by
itself sufficient to reduce signaling through this pathway.
The effect of proteasome inhibitors on p44/42 MAPK signal-
ing was tested further in concentration and time dependence
studies. A1N4-myc (Fig. 1B, left panel) and MDA-MB-231 cells
(Fig. 1B, right panel) exposed to Z-LLF-CHO both exhibited
decreased phospho-ERK-1/2 levels in a manner that was de-
pendent on the proteasome inhibitor concentration. Exposure
to lactacystin also resulted in a concentration-dependent de-
crease in phosphorylated p44 and p42 MAPK (Fig. 1C, left and
right panels). Time-course experiments revealed that A1N4-
myc cells were especially sensitive in that phospho-MAPK lev-
els decreased as early as 3 h after addition of either Z-LLF-
CHO (Fig. 1D, left panel) or lactacystin (Fig. 1E, left panel), and
decreased further with prolonged incubation in a time-depend-
ent fashion. MDA-MB-231 cells showed a similar time depend-
ence, although loss of active MAPK was somewhat delayed, and
did not begin until 6 h after exposure to Z-LLF-CHO (Fig. 1D,
right panel) or lactacystin (Fig. 1E, right panel). Inactivation of
MAPK signaling was more transient with lactacystin for both
A1N4-myc and MDA-MB-231 cells, however, in that phospho-
ERK-1/2 levels reached their nadir at 9 h and then began to
return to baseline at 12 h. Because lactacystin is a reactive
compound with a short half-life (46), the possibility was con-
sidered that the decline in MAPK inactivation after 9 h was
because of the disappearance of the active proteasome inhibi-
tor. When additional lactacystin was added to cell cultures
after 6 h of incubation, phospho-p44/42 MAPK levels continued
to decrease at 9 and 12 h (data not shown), further supporting
the link between proteasome inhibition and MAPK
inactivation.
Decreased ERK-1/2 Signaling Is Caused by a Phosphatase—
Phosphorylation of p44/42 MAPK is catalyzed by the mitogen-
activated protein kinase kinase MEK (29, 30), so the possibility
was considered that decreased phospho-ERK-1/2 levels were
because of decreased MEK activity. When A1N4-myc cells ex-
posed to Z-LLF-CHO in time-course experiments were ana-
lyzed for their content of active phospho-MEK by Western
blotting, however, no significant changes were noted (Fig. 2A),
and indeed phospho-MEK levels seemed better preserved in
the inhibitor-treated cells. A similar pattern was noted for
lactacystin-treated A1N4-myc cells (data not shown), suggest-
ing that under these conditions MEK activity was not signifi-
cantly decreased, and therefore likely did not contribute to
decreased phospho-ERK-1/2 levels. Another mechanism used
by cells to control MAPK activity is through the action of
protein phosphatases, including both phosphoprotein phos-
phatases 2A (PP2A) and 1 (PP1), as well as dual specificity
protein phosphatases (reviewed in Refs. 47 and 48). To deter-
mine whether any of these phosphatases might be involved,
cells were preincubated either with okadaic acid at concentra-
FIG. 1. p44/42 MAPK in cells exposed to proteasome inhibitors.
A, A1N4-myc (left panel) or MDA-MB-231 cells (right panel) were mock-
treated, exposed to vehicle, the inactive precursor Z-LLF-OH at 100 M,
the active peptidyl aldehyde proteasome inhibitor Z-LLF-CHO at 100
M, or the structurally unrelated specific proteasome inhibitor lacta-
cystin at 10 M, for 6 (A1N4-myc) or 12 (MDA-MB-231) h. The impact on
p44/42 MAPK signaling was evaluated by Western blotting using anti-
bodies directed against the dually phosphorylated, active forms of
ERK-1 and -2. Equal loading was confirmed by reprobing with antibod-
ies that recognize ERK in a phosphorylation status-independent man-
ner, and then with antibodies directed against HSC-70. The migration
of pre-stained and biotinylated protein molecular size markers are
indicated. All panels in this figure are representative results from one
of two independent experiments. B, A1N4-myc or MDA-MB-231 cells
were exposed to the indicated concentrations of Z-LLF-CHO for 6 or
12 h as above. The -fold decrease in phospho-MAPK abundance is
shown in relation to vehicle-treated cells and is adjusted for loading of
HSC-70 (data not shown). Higher concentrations of Z-LLF-CHO than
those shown for MDA-MB-231 cells did not result in increased MAPK
inactivation. C, A1N4-myc or MDA-MB-231 cells were exposed to the
indicated concentrations of lactacystin for either 9 (A1N4-myc) or 12
(MDA-MB-231) h. D and E, A1N4-myc or MDA-MB-231 cells were
exposed to 5 M Z-LLF-CHO (PI) (panel D), 5 M lactacystin (panel E),
or vehicle (V) for 3, 6, 9, and 12 h prior to lysate preparation, whereas
mock-treated cells (M) were fed with fresh medium for 5 min. The -fold
decrease of phospho-MAPK levels is shown in relation to vehicle-treated
cells harvested in parallel at each time point and is adjusted for loading
of HSC-70.
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tions that would inactivate both PP2A and PP1 (49–51), so-
dium orthovanadate to inactivate tyrosine phosphatases (52,
53), or both, and then exposed to a proteasome inhibitor. Al-
though okadaic acid itself caused a mild increase in phospho-
ERK-1/2 levels, this inhibitor was unable to block proteasome
inhibitor-induced dephosphorylation of p44/p42 MAPK in ei-
ther A1N4-myc (Fig. 2B, left panel) or MDA-MB-231 cells (Fig.
2B, right panel). When calyculin A was used, another cell-
permeable inhibitor of PP2A and PP1 (54), it also proved un-
able to block inactivation of ERK-1/2 (results not shown), fur-
ther supporting that this dephosphorylation did not occur
predominantly through a PP1- or PP2A-dependent mechanism.
Sodium orthovanadate, in contrast, not only increased the
baseline levels of phospho-ERKs, but also significantly inhib-
ited the ability of proteasome inhibition to induce ERK dephos-
phorylation in A1N4-myc cells (Fig. 2B, left panel), and almost
completely did so in MDA-MB-231 cells (Fig. 2B, right panel).
These results suggested that induction of a vanadate-sensitive,
but okadaic acid-insensitive, protein-tyrosine phosphatase was
responsible for MAPK dephosphorylation.
Although there are several dual specificity phosphatases
involved in regulation of MAPK activity (47, 48), mitogen-
activated protein kinase phosphatase-1 (MKP-1) seemed wor-
thy of special attention because it is induced by heat shock and
genotoxic stress (55–57), and proteasome inhibition activates
the heat shock response (22, 58). In addition, the nonspecific
inhibitor ALLN has been reported to increase MKP-1 expres-
sion and ubiquitin conjugates of MKP-1, supporting a role for
the proteasome in MKP-1 degradation (36), although in an-
other study ALLN was unable to increase MKP-1 levels (35).
The expression of MKP-1 in A1N4-myc and MDA-MB-231 cells
exposed to Z-LLF-CHO was therefore evaluated by Western
blotting. Compared with mock-, vehicle-, and control peptide-
treated cells, all of which had low levels of MKP-1 expression,
in both A1N4-myc (Fig. 2C, left panel) and MDA-MB-231 cells
(Fig. 2C, right panel) a significant induction of MKP-1 was noted.
To determine whether proteasome inhibition alone was sufficient
to induce MKP-1, lactacystin was used and it was also able to
increase cellular levels of this phosphatase. Moreover, there ap-
peared to be a correlation between MKP-1 expression and phos-
pho-MAPK content, because MDA-MB-231 cells treated with
lactacystin had the lowest MKP-1 expression and had the least
dephosphorylation of ERK-1/2 (compare Figs. 2C (right panel)
and 1A (right panel)).
MKP Induction Correlates with MAPK Dephosphoryl-
ation—To further probe the possible link between proteasome
inhibitor-induced MKP-1 expression and dephosphorylation of
p44/42 MAPK, the concentration and time dependence of
MKP-1 induction was studied. In both A1N4-myc (Fig. 3A, left
panel) and MDA-MB-231 cells (Fig. 3A, right panel), MKP-1
was induced in a manner dependent on the concentration of
Z-LLF-CHO. Inhibition of the proteasome alone was sufficient
for this induction to be seen, because lactacystin demonstrated
a similar ability (Fig. 3B, left and right panels, respectively).
During time-course experiments, Z-LLF-CHO was noted to
induce MKP-1 expression as early as after 3 h, with a subse-
quent increase in a time-dependent manner in A1N4-myc (Fig.
3C, left panel) and MDA-MB-231 cells (Fig. 3C, right panel).
Lactacystin induced MKP-1 by 3 h as well, but unlike for
Z-LLF-CHO, this induction then peaked at 6 h, and slowly
declined subsequently (Fig. 3D, right and left panels). A com-
parison of MKP-1 induction (Fig. 3) with p44/42 MAPK dephos-
phorylation (Fig. 1) showed that both increased in a protea-
some inhibitor concentration-dependent fashion, although a
more continuous induction of MKP-1 was seen. Phospho-ERK-
1/2 levels appeared to reach a nadir value, and some dually
phosphorylated kinase was always detectable. Comparing the
time-course studies, MKP-1 induction appeared to somewhat
precede p44/42 MAPK dephosphorylation and, in the case of
lactacystin, when MKP-1 levels declined beginning at 9 and
then 12 h, phospho-MAPK levels recovered. These findings are
consistent with the hypothesis that induction of MKP-1 is
responsible in part for the dephosphorylation of ERK-1 and -2.
To more directly probe the relationship between MKP induc-
tion and MAPK dephosphorylation, antisense oligonucleotides
and cell lines expressing MKP-1 in an antisense direction were
employed. Both of these strategies resulted in only modest
inhibition of MKP-1 expression, which mildly decreased MAPK
dephosphorylation (results not shown). Because induction of
MKP-1 in other systems has been noted to be dependent on
gene expression, it therefore can be quantitatively inhibited by
actinomycin D (59) and Ro-31-8220 (60). The effect of these
agents on proteasome inhibitor-induced MKP-1 expression was
therefore evaluated by preincubating cells prior to addition of
Z-LLF-CHO. Actinomycin D completely blocked the ability of
the proteasome inhibitor to induce MKP-1 in both A1N4-myc
(Fig. 3E, left panel) and MDA-MB-231 (Fig. 3E, right panel)
cells, as did Ro-31-8220. Both compounds increased the basal
levels of dually phosphorylated ERK-1 and -2 compared with
vehicle-treated controls. Furthermore, in the course of prevent-
ing induction of MKP-1, these agents significantly blocked the
ability of the proteasome inhibitor to induce dephosphorylation
of p44/42 MAPK, suggesting that MKP-1 was a major contrib-
utor to this inhibitor-mediated activity. When lactacystin was
FIG. 2. MAPK inactivation and cellular phosphatases. A, A1N4-
myc cells were exposed to 5 M Z-LLF-CHO (PI) or vehicle (V) for 3, 6,
9, and 12 h as indicated, and the impact on the kinase upstream from
MAPK, MEK, was assayed using phosphospecific MEK antibodies. M,
mock-treated. Loading was confirmed by stripping and reprobing with
an MEK antibody that was not phosphorylation state-dependent, and
also by stripping and reprobing with an antibody to GRP-94. All panels
in this figure are representative results from one of two independent
experiments. B, A1N4-myc or MDA-MB-231 cells were preincubated
with either okadaic acid (OA) at 30 nM, sodium orthovanadate (OV) at
1 mM for 60 min, or the two together (OAOV), and then treated either
with vehicle () or with Z-LLF-CHO at 10 M () for 6 (A1N4-myc) or
12 (MDA-MB-231) h. Levels of dually phosphorylated ERK-1/2 were
then determined by Western blotting. The -fold decrease of phospho-
MAPK levels is shown in relation to vehicle-treated cells for Z-LLF-
CHO, and for phosphatase-treated cells when combinations of phospha-
tase and proteasome inhibitors were used. Data were adjusted for
loading of HSC-70. C, A1N4-myc or MDA-MB-231 cells were treated
with controls or the proteasome inhibitors Z-LLF-CHO or lactacystin,
as described in the legend to Fig. 1, and the impact on MKP-1 expres-
sion was assayed by Western blotting. Equal loading was confirmed by
reprobing with antibodies that recognize HSC-70. The migration of
pre-stained and biotinylated protein molecular size markers is
indicated.
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used in these assays, actinomycin D and Ro-31-8220 again
blocked MKP-1 expression and inhibited MAPK dephosphoryl-
ation (results not shown).
Although proteasome inhibitor-mediated MAPK inactivation
could be significantly decreased by blocking MKP-1, some de-
crease in phospho-MAPK levels was still notable, suggesting
the presence of another phosphatase. Expression of the related
dual specificity phosphatase MKP-2 under these conditions
was therefore evaluated because it has been reported to be
induced by ALLN (36). MKP-2 was noted to be present in both
A1N4-myc (Fig. 3E, left panel) and MDA-MB-231 (Fig. 3E,
right panel) cells that were mock- and vehicle-treated. Protea-
some inhibition with Z-LLF-CHO resulted in a mild induction
of MKP-2 in both cell lines, which was much more modest than
that seen with MKP-1. Actinomycin D and Ro-31-8220 both
decreased MKP-2 levels, but subsequent addition of a protea-
some inhibitor was still able to increase the expression of this
phosphatase. These results support the hypothesis that MKP-1
is the major agent of MAPK dephosphorylation induced by
proteasome inhibition, but other phosphatases such as MKP-2
may play a role as well.
MAPK Blockade Enhances Proteasome Inhibitor-mediated
Apoptosis—The p44/42 MAPK pathway plays a role in apopto-
sis (28–30), and it was therefore of interest to examine the
possibility that proteasome inhibitor-mediated loss of phospho-
ERK-1/2 was involved in the induction of programmed cell
death. Because MEK activity had not been affected by protea-
some inhibitors (Fig. 2A), the possibility was considered that
MEK inhibition, resulting in a further decrease in phospho-
MAPK levels, would increase apoptosis. A1N4-myc (Fig. 4A)
and MDA-MB-231 cells (Fig. 4B) were therefore preincubated
with one of two structurally unrelated MEK inhibitors, either
PD 98059 (61, 62) or U0126 (63), and then exposed to Z-LLF-
CHO or lactacystin. The MEK inhibitors themselves had a
small impact on apoptosis compared with vehicle controls. PD
98059, for example, increased apoptosis of A1N4-myc cells by
only 1.06-fold, whereas apoptosis of MDA-MB-231 cells was
increased by 1.11-fold (results not shown). Both proteasome
inhibitors had a much greater impact on apoptosis, with lacta-
cystin increasing apoptosis in A1N4-myc cells by 1.38-fold, and
in MDA-MB-231 cells by 2.34-fold (results not shown). When
the combination of these agents with proteasome inhibitors
was compared with proteasome inhibitors alone, however, a
significant increase in apoptosis was noted in both A1N4-myc
(Fig. 4A) and MDA-MB-231 cells (Fig. 4B). Combinations of
lactacystin and PD 98059 enhanced apoptosis by 1.87-fold in
A1N4-myc cells, and 3.02-fold in MDA-MB-231 cells. U0126
was even more active in this regard, in that with lactacystin it
increased apoptosis by 2.65- and 3.89-fold in these two cell
lines, respectively (Fig. 4, A and B). Analysis of phospho-MAPK
levels revealed that the combination of an MEK inhibitor and a
proteasome inhibitor resulted in further decreases in the abun-
dance of dually phosphorylated ERK-1/2 than was induced by
the proteasome inhibitor alone (results not shown).
PD 98059 and U0126 are fairly specific inhibitors of MEK,
but the possibility was considered that their enhancement of
proteasome inhibitor-mediated apoptosis could be occurring
through effects other than those on the p44/42 MAPK pathway.
To evaluate this, cell lines were prepared that expressed the
K52R ERK-2 mutant, the kinase activity of which is 5% of
that of wild-type ERK-2 (44). Both the vector-transfected
(A1N4-myc/pLPCX) and dominant negative (A1N4-myc/
pLPCX-ERK-K3R) cells underwent apoptosis after treatment
with Z-LLF-CHO or lactacystin. Compared with A1N4-myc/
pLPCX cells, however, the A1N4-myc/pLPCX-ERK-K3R cells
underwent 2.31-fold more apoptosis after exposure to Z-LLF-
CHO (Fig. 4C), and 1.38-fold more apoptosis after exposure to
lactacystin (Fig. 4C). MDA-MB-231 clones expressing the K52R
ERK-2 mutant could not be isolated, suggesting a greater de-
pendence for survival on p44/42 MAPK function in these cells,
but such lines were successfully prepared from BT-474 human
mammary carcinoma cells (41). When these cells are exposed to
proteasome inhibitors, levels of dually phosphorylated ERK-1
and -2 decline, whereas MKPs are induced, in a manner anal-
ogous to that described above for A1N4-myc and MDA-MB-231
cells (results not shown). BT-474 vector-transfected cells (BT-
474/pLPCX) and those expressing dominant negative ERK-2
(BT-474/pLPCX-ERK-K3R) were induced into apoptosis by
Z-LLF-CHO or lactacystin. The K52R ERK-2 mutants, how-
ever, underwent 2.07- and 1.71-fold more apoptosis after Z-
LLF-CHO or lactacystin treatment, respectively, compared
with the vector-transfected controls (Fig. 4D).
FIG. 3. MKP expression in cells treated with proteasome in-
hibitors. A, A1N4-myc or MDA-MB-231 cells were exposed to the
indicated concentrations of Z-LLF-CHO for either 6 (A1N4-myc) or 12
(MDA-MB-231) h. The impact on MKP-1 expression was assayed by
Western blotting, and loading was confirmed by stripping and reprob-
ing with HSC-70 antibodies (data not shown). The -fold induction of
MKP-1 is shown in relation to vehicle-treated cells and is adjusted for
HSC-70. All panels are representative results from one of two independ-
ent experiments. B, A1N4-myc or MDA-MB-231 cells were exposed to
the indicated concentrations of lactacystin for either 9 (A1N4-myc) or 12
(MDA-MB-231) h. The -fold induction of MKP-1 is shown. C and D,
A1N4-myc or MDA-MB-231 cells were exposed to 5 M Z-LLF-CHO
(panel C) or 5 M lactacystin (panel D) for the indicated times, whereas
mock-treated cells (M) were fed with fresh medium for 5 min. The -fold
induction of MKP-1 is shown in relation to vehicle-treated cells har-
vested in parallel at each time point and is adjusted for loading of
HSC-70. E, A1N4-myc or MDA-MB-231 cells were preincubated for 30
min with 3 g/ml actinomycin D or 5 M Ro-31-8220. They were then
treated with Z-LLF-CHO (PI) at 10 M or vehicle (V) for 6 h, in parallel
with mock-, vehicle-, and inhibitor-treated cells without actinomycin D
or Ro-31-8220. Each upper panel shows the impact on MKP-1 expres-
sion, as determined by Western blotting. The middle panels show phos-
pho-ERK-1/2 content, with the -fold decrease of phospho-MAPK levels
indicated in relation to vehicle-treated cells for Z-LLF-CHO, and for
actinomycin D (Act-D)- or Ro-treated cells when combinations were
used, all with corrections for loading of HSC-70. MKP-2 expression is
shown in the lower panels, which were generated by stripping and
reprobing the MKP-1 blots with anti-MKP-2 antibody. This latter rea-
gent has some cross-reactivity with MKP-1, which can be seen in those
cells treated with the proteasome inhibitor alone. Induction of MKP-2 is
shown in relation to HSC-70 as a loading control.
Proteasome Inhibition, p44/42 MAPK, and Apoptosis27868
MAPK Activation Decreases Proteasome Inhibitor-mediated
Apoptosis—If proteasome inhibitor-mediated apoptosis occurs
in part through decreased p44/42 MAPK signaling, then in-
creased activation of this pathway should decrease apoptosis.
To evaluate this possibility, A1N4-myc and MDA-MB-231 cells
were exposed to Z-LLF-CHO or lactacystin either in the pres-
ence or absence of EGF, which stimulates the ERK-1/2 signal
transduction cascade (reviewed in Refs. 64 and 65). In A1N4-
myc cells epidermal growth factor decreased Z-LLF-CHO-me-
diated apoptosis by 2.44-fold and lactacystin-induced apoptosis
by 1.39-fold (Fig. 5A). In MDA-MB-231 cells, this effect of EGF
was 1.69-fold for both proteasome inhibitors. EGF can also
activate other anti-apoptotic pathways in some breast cancer
cells, such as the protein kinase B/Akt serine/threonine kinase
(66). Cell lines expressing the D319N ERK-2 sevenmaker mu-
tant that has significantly reduced sensitivity to dephosphoryl-
ation by MKP-1 and -2 (43) were therefore prepared. Expres-
sion of this dominant-positive allele in A1N4-myc cells
inhibited apoptosis by 1.43- and 1.30-fold when they were
treated with Z-LLF-CHO and lactacystin, respectively, com-
pared with vector-containing controls (Fig. 5C), whereas in
MDA-MB-231 cells lactacystin-induced apoptosis was inhibited
by 1.52-fold (Fig. 5D). The finding that blockade of MAPK
activity using either pharmacologic or dominant-negative con-
structs enhances apoptosis, whereas MAPK activation with
EGF or dominant positive mutants inhibits programmed cell
death, strongly supports the hypothesis that inhibition of sig-
naling through p44/42 MAPK plays a role in proteasome inhib-
itor-mediated apoptosis.
DISCUSSION
The ability of proteasome inhibitors to induce apoptosis in
tumor-derived cells lines and animal models of human malig-
nancies (10–12) has sparked interest in their use as agents in
cancer therapeutics (reviewed in Ref. 67). A better understand-
ing of the underlying mechanisms by which proteasome inhib-
itors act will allow a rational use of these compounds and
contribute to the design of novel combination regimens. Pro-
teasome inhibitors have been reported to inhibit nuclear trans-
location and signaling through the NF-B pathway (10, 11),
FIG. 4. Impact of MAPK blockade on proteasome inhibitor-
mediated apoptosis. A, A1N4-myc cells were preincubated with ei-
ther 20 M PD 98059 or U0126 for 2 h and then treated with 3 M
Z-LLF-CHO or 4 M lactacystin for an additional 6 h. The extent of any
induced apoptosis was determined using the Cell Death Detection
ELISAPLUS kit using vehicle-treated cells as controls. Apoptosis in-
duced by either of the two proteasome inhibitors alone in A1N4-myc
cells was then arbitrarily set at 1.00, and apoptosis induced by combi-
nations with PD 98059 or U0126 is expressed in relation to that value
as a -fold increase over 1.00. Note that the results described in the text
are expressed as -fold induction compared with vehicle controls. A black
bar represents the expected impact of PD 98059 or U0126 alone based
on control experiments, and any excess apoptosis above that level
suggests a synergistic interaction between the proteasome and MEK
inhibitors. All panels represent the results of four experiments, and the
mean -fold increase in apoptosis is shown along with the standard error
of the mean. B, MDA-MB-231 cells were preincubated with either 20 M
PD 98059 or U0126 for 2 h and then treated with 4 or 5 M lactacystin
for 12 h. The -fold induction of apoptosis over controls was evaluated,
calculated, and expressed as above. C, A1N4-myc cells containing either
the pLPCX vector, or those expressing the dominant negative K52R
ERK-2 mutant, were treated with Z-LLF-CHO or lactacystin, and the
induction of apoptosis was compared with vehicle-treated cells. The
results in pLPCX-containing cells were then arbitrarily set at 1.00, and
programmed cell death induced in mutant ERK-containing cells was
expressed as the -fold increase compared with 1.00. To rule out the
possibility of clonal variation, two separate single-cell clones were as-
sayed and the results presented are the mean of the two. D, pooled
clones of BT-474 cells containing either pLPCX or the K52R ERK-2
mutant were treated with 10 M Z-LLF-CHO or 20 M lactacystin for
18 h. The results were analyzed and are presented as described in
panel C.
FIG. 5. Impact of increased MAPK activity on proteasome in-
hibitor-mediated apoptosis. A and B, A1N4-myc (panel A) or MDA-
MB-231 cells (panel B) were exposed to Z-LLF-CHO or lactacystin, as
described in the legend to Fig. 4, either in complete medium or medium
supplemented with EGF at 10 ng/ml. Apoptosis induced in the presence
of complete medium was arbitrarily set at 1.00, and programmed cell
death in the presence of EGF was expressed in relation to this value.
The -fold inhibition referred to in the text is the inverse of the values
presented in the graph. All panels represent the results of three to four
experiments performed in duplicate. C and D, The impact of the phos-
phatase-resistant ERK sevenmaker mutant on proteasome inhibitor-
mediated apoptosis was evaluated in A1N4-myc (panel C) and MDA-
MB-231 cells (panel D), with apoptosis of vector-containing cells
arbitrarily set at 1.00 as described in Fig. 4. Two separate single cell
clones were evaluated, and the results were combined. Z-LLF-CHO was
not tested in the MDA clones.
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and to activate signaling through the c-Jun N-terminal kinase
and p38 MAPKs (22). Their effects on another ubiquitous sig-
naling cascade, the p44/42 MAPK or ERK-1/2 pathway, have
not been well characterized, however, with proteasome-specific
inhibitors. Although activity of this pathway is associated with
cellular proliferation and apoptosis in many cells (28–30), its
importance has been particularly well studied in breast cancer.
Signaling by the erbB receptor tyrosine kinase family, which
occurs in part through p44/42 MAPK, has been implicated in
the development and progression of breast cancer, and high
expression of c-erbB-2 (HER-2/neu) and the homologous EGF
receptor (c-erbB-1) is a poor prognostic sign (reviewed in Ref.
68). Indeed, elevated activity of ERK-1/2 alone has been sug-
gested to have prognostic significance for disease-free survival
of breast cancer patients (69). Given this critical role for MAPK
activity in breast cancer, breast epithelium- and tumor-derived
cell lines were chosen as the subjects of this study.
Inhibition of the proteasome with two structurally distinct
inhibitors, including the tripeptidyl aldehyde Z-LLF-CHO and
the Streptomyces product lactacystin, resulted in decreased
levels of dually phosphorylated ERK-1 and -2 (Fig. 1A) in a
concentration- and time-dependent fashion (Fig. 1, B–E). This
decrease took place despite the continued presence of either
fetal bovine serum in the case of MDA-MB-231 cells, or even
serum supplemented with EGF in the case of A1N4-myc cells.
A recent investigation of multiple myeloma cells treated with
one concentration of PS-341 found that activation of phospho-
MAPK by interleukin 6 or binding to bone marrow stroma was
blocked by this proteasome inhibitor (37). Because this com-
pound (16), like Z-LLF-CHO (38, 45) and lactacystin (46), is
able to inhibit the chymotrypsin-like activity of the protea-
some, it seems that blockade of ERK-1/2 signaling may be a
common property of proteasome inhibitors. One possible excep-
tion was recently reported by Vrana and Grant (70), who noted
that lactacystin did not induce ERK phosphorylation in U937
monocytic leukemia cells. However, at the concentration of 1.0
M used in their study, we also found a small impact on MAPK
(Fig. 1C), and it is therefore possible that higher lactacystin
concentrations would have a similar effect on U937 cells. A
second possible exception is the work of Torres et al. (35), who
demonstrated that the nonspecific inhibitor ALLN at 100 M
did not decrease dually phosphorylated MAPK levels in Balb/c
3T3 cells. They evaluated cells after a 6-h exposure, however,
and in our studies we also found that Z-LLF-CHO had only
slight effects on MAPK at 6 h in MDA-MB-231 cells (Fig. 1D,
right panel), suggesting that a longer exposure in their system
could have uncovered a loss of active MAPK.
Although phospho-p44/42 MAPK levels were decreased by
proteasome inhibition the activity of the MEK kinase appeared
not to be affected (Fig. 2A), suggesting that MAPK dephospho-
rylation was because of a phosphatase. Several lines of evi-
dence implicated MKPs as the major phosphatases involved in
this process. MKP-1 is induced by heat shock and genotoxic
stress (55–57), whereas proteasome inhibitors activate the heat
shock response (22, 58). In addition, the nonspecific proteasome
inhibitor ALLN was reported to increase MKP-1 and -2 expres-
sion, along with ubiquitin-MKP-1 conjugates (36), supporting a
role for the proteasome in MKP turnover. We found that
MKP-1 was strongly induced by both Z-LLF-CHO and lacta-
cystin (Fig. 2C), demonstrating that inhibition of the protea-
some alone was sufficient to increase MKP-1 expression. This
occurred in a concentration- and time-dependent manner (Fig.
3, A–D) that was consistent with an effect on phospho-MAPK
levels. Quantitative blockade of MKP-1 induction using either
actinomycin D or Ro-31-8220 almost completely preserved the
activity of ERK-1/2 (Fig. 3E). The experiments with actinomy-
cin D demonstrate for the first time that, whereas some of the
proteasome inhibitor-mediated increase in MKP-1 expression
may be because of protein stabilization, a sizable proportion of
it is likely because of induction of MKP transcription. Because
MKP-1 is widely expressed (47, 48), it may also be responsible
for the ability of PS-341 to inhibit interleukin 6-induced MAPK
activation in myeloma cells (37), although mechanistic studies
were not reported by the authors. A possible exception is pro-
vided by the work of Torres et al. (35), who found no induction
of MKP-1 in their Balb/c 3T3 system after 6 h. It is again
possible that longer exposures might uncover MKP induction,
or that this may prove to be a cell type-specific effect. In
addition, the possibility that other proteasome inhibitor-in-
duced phosphatases play a role in MAPK inactivation cannot
be excluded. Expression of the MKP-3 and VHR dual-specificity
phosphatases was not increased in these cells (results not
shown), but the serine/threonine protein phosphatase 5 is re-
portedly induced by proteasome inhibition in MCF-7 breast
carcinoma cells (71). A combination of these and other phos-
phatase activities may be required to fully dephosphorylate
ERK-1 and -2.
Given the central role of the proteasome in normal cellular
homeostasis, the pro-apoptotic effects of proteasome inhibitors
are likely to be because of an impact on several important
pathways. Because signaling through the Ras/Raf/MEK/ERK
cascade is crucial to many cellular processes, however, inhibi-
tion of p44/42 MAPK activity may prove to be one of the more
important effects of these inhibitors. To evaluate this possibil-
ity, we first postulated that, if MAPK inhibition was important
to proteasome inhibitor-mediated apoptosis, further MAPK
blockade should enhance programmed cell death. This proved
to be the case, because the MEK inhibitors PD 98059 and
U0126 enhanced both Z-LLF-CHO- and lactacystin-induced
apoptosis in A1N4-myc (Fig. 4A) and MDA-MB-231 cells (Fig.
4B), and a dominant negative ERK-2 construct showed a sim-
ilar impact (Fig. 4, C and D). We then postulated that, if MAPK
inhibition played a role in proteasome inhibitor-mediated apo-
ptosis, opposing this inactivation should inhibit programmed
cell death. MAPK stimulation with EGF did indeed inhibit the
induction of programmed cell death (Fig. 5, A and B), as did the
use of a mutant MAPK that was resistant to dephosphorylation
by MKPs (Fig. 5, C and D). Dysregulation of MAPK function
therefore appears to be an important step for proteasome in-
hibitor-mediated apoptosis in these cell lines. Recent work by
Vrana and Grant (70) also concluded that the MAPK cascade
was an important target during the synergistic induction of
apoptosis in U937 cells treated with a combination of bryosta-
tin and lactacystin. They found, however, that lactacystin pro-
longed the activation of MAPK induced by the protein kinase C
activator bryostatin when the two agents were used concur-
rently, and that MEK inhibitors attenuated apoptosis induced
by this regimen (70). Because the impact of MEK inhibitors and
lactacystin was not studied in the absence of bryostatin, it is
possible that this difference is because of a specific interaction
of proteasome inhibitors with the latter agent. Alternatively, it
may point to a cell type-specific effect, which, if documented,
would have important clinical implications, because it would
suggest that a proteasome inhibitor/MEK inhibitor regimen
would enhance tumor killing in patients with breast cancer,
but might antagonize it in those with monocytic leukemia.
In addition to shedding light on the potential mechanisms by
which proteasome inhibitors affect tumor growth, the current
study allows the formation of hypotheses about their optimal
use in a clinical setting. Breast tumors overexpressing c-erbB-2
and c-erbB-1 might have been hypothesized to be more suscep-
tible to proteasome inhibitor-mediated apoptosis because of a
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greater reliance on the survival signals communicated through
the Ras/Raf/MEK/MAPK pathway, and the ability of protea-
some inhibitors to decrease MAPK activity. The studies with
EGF, however, suggest the opposite, in that MAPK stimulation
opposed the induction of programmed cell death. If this proves
to be the case in in vivo models, these inhibitors should be
targeted especially toward patients with low expression of c-
erbB-2 and c-erbB-1, whereas those with high expression might
benefit from a proteasome inhibitor in combination with an
MEK inhibitor. Such a regimen would represent a welcome
addition to the chemotherapeutic armamentarium, because
these patients have a poorer prognosis with currently available
agents (68). The ability of proteasome inhibitors to block MAPK
activity also suggests that they should be effective in combina-
tion with Taxol®, another agent used in patients with breast
cancer. This inhibitor of microtubule assembly has been re-
cently reported to activate MAPK, and pharmacologic agents
such as U0126 that inhibited MEK activity and MAPK phos-
phorylation enhanced Taxol®-induced cytotoxicity (72). Al-
though proteasome inhibitors inactivate MAPK through a dif-
ferent mechanism, they should similarly enhance the anti-
tumor efficacy of Taxol®, suggesting that trials of this
combination in patients with breast cancer are warranted.
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